Apremilast

Apremilast
Product Description

As one of the largest API supplier worldwide, we are your reliable partner for the supply of high quality commercial quantities of Apremilast

Dr. Reddy's Laboratories Ltd.

  • IN
  • 2019
    On CPHI since
Specifications
  • CAS Registry Number
    608141-41-9

Dr. Reddy's Laboratories Ltd.

  • IN
  • 2019
    On CPHI since

More Products from Dr. Reddy's Laboratories Ltd. (4)

  • Abiraterone Acetate

    Product Abiraterone Acetate

    We supply Abiraterone Acetate in bulk quantities. Learn more on api.drreddys.com.
  • Atorvastatin

    Product Atorvastatin

    We supply Atorvastatin as a generic API in commercial quantities.
  • Apremilast

    Product Apremilast

    As one of the largest API supplier worldwide, we are your reliable partner for the supply of high quality commercial quantities of Apremilast
  • Apremilast

    Product Apremilast

    As one of the largest API supplier worldwide, we are your reliable partner for the supply of high quality commercial quantities of Apremilast

Dr. Reddy's Laboratories Ltd. resources (4)

  • News CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 1

    This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force? 
  • News Novartis agrees for copies to be made of cancer drug to reach poorer countries

    Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. 
  • News Aurigene Pharmaceutical Services to expand biologics CDMO capacity with a new biomanufacturing facility

    Aurigene Pharma announces the construction of a state-of-the art development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors.
    As a first step of investment plan, Aurigene is investing $40m in an R&D and pilot scale facility at Genome Valley, a well-known Biotechnology Park in Hyderabad. This facility will meet the process development and clinical supply needs of global biotech companies. The facility is planned to be fully operational in first half of 2024.This complements Aurigene’ s strong foundation in biotherapeutics discovery, contributing to accelerating global R&D-driven (bio)pharma companies’ biologics journey to the market by offering end-to-end and high-quality services for antibodies, proteins, and viral vectors.
  • News CPHI Podcast Series: The importance of Pharma 4.0 to innovation leads in India

    In this latest episode from the CPHI Podcast Series, Digital Editor Lucy Chard speaks to Sanjay Sharma, Global Head of Manufacturing, from Dr Reddy’s. Sanjay has over 26 years of experience in roles encompassing sales, the supply chain, and technical operations.